SAT0287 Long-Term Safety Of Ustekinumab: 5 Years of Follow-Up from the Psoriasis Clinical Development Program Including Patients with Psoriatic Arthritis — Kim Papp (2013) | RDL Network
SAT0287 Long-Term Safety Of Ustekinumab: 5 Years of Follow-Up from the Psoriasis Clinical Development Program Including Patients with Psoriatic Arthritis
Kristian Reich, Kim Papp, Christopher Em Griffiths, Philippe Szapary, Newman Yeilding, Yasmine Wasfi, Elyssa Ott, Ming Chun Hsu, Mark Lebwohl, Kenneth B. Gordon
Kim Papp, Christopher Em Griffiths, Kenneth B. Gordon, Mark Lebwohl, Philippe Szapary, Yasmine Wasfi, Daphne Chan, M.-C. Hsu, Vincent Ho, Pierre‐Dominique Ghislain, Bruce Strober, Kristian Reich
PCM van de Kerkhof, Kristian Reich, C Leonardi, Andrew Blauvelt, Nehal Nailesh Mehta, TF Tsai, R. You, Phil Papanastasiou, M. Milutinovic, Christopher Em Griffiths
Jorge Belardi, Alan C. Yeung, Martin B. Leon, Patrick W. Serruys, Ian T. Meredith, Stephan Windecker, Sigmund Silber, Franz‐Josef Neumann, Petr Widimský, Shigeru Saito, Joseph M. Massaro, Laura Mauri
Ganesh Manoharan, Franz‐Josef Neumann, Stephan Windecker, Martin B. Leon, Ian T. Meredith, Shigeru Saito, Patrick W. Serruys, Sigmund Silber, Alan C. Yeung, Jorge Belardi, Petr Widimský, Laura Mauri
.webp){kind=small}
Discussion(0)
No comments yet. Be the first to comment.